Learn what counts as evidence →
Separate personal stories, animal experiments and controlled human research before interpreting a benefit.
Your Parish field guide · Personal learning
Patient, caregiver or curious newcomer
Start here whether you are new to the subject or already comfortable reading science. Learn how to identify a product, judge a claim and prepare questions for care. Technical words are explained as they appear; the glossary and linked readings let you go further.
Your takeaway
Leave with a short, useful appointment brief and a clearer distinction between a medicine, an investigational compound and an online claim.
Start with these three chapters
Identify the preparation, distinguish measured benefits from promises, then prepare your care conversation.
- Know which product the evidence describes
- Read a claim without losing its limits
- Prepare a useful care conversation
Then use the reading path and books for more depth, and complete the learning worksheet to record what you found.
Know which product the evidence describes
A molecule name is a starting point, not a complete product description. Record the active ingredient, chemical form, formulation, route, manufacturer or compounder and the document date. Products using similar names may differ in ways that matter. A result for one preparation does not automatically establish the performance of another.
FDA approval concerns a particular drug product and its authorized labeling. A facility registration, product listing or National Drug Code does not mean FDA has approved the product. A company can have legitimate paperwork for one activity without every product or claim being authorized.
Compounded drugs are prepared under a different framework and are not FDA-approved. They can serve particular patient needs, but FDA does not review each compounded product for safety, effectiveness and quality before marketing in the way it reviews approved medicines.
Investigational means a product or use is being studied; it does not mean success is established. Research-use labeling concerns a claimed purpose and cannot establish suitability for human use. Keep regulatory status, analytical quality and clinical evidence as three separate entries. None can substitute for the other two.
Build a simple comparison: what the paper studied, what the official label describes, and what the current document or service names. Mark missing information rather than filling it with a brand assumption. This comparison is useful for a patient preparing questions and for a professional reviewing a brochure.
Pharmacy types
Section 503A covers compounding for an identified individual patient, including by a pharmacist in a state-licensed pharmacy, subject to its conditions. Section 503B covers registered outsourcing facilities that remain subject to current good manufacturing practice (CGMP), a system of manufacturing quality requirements. These facilities can supply office stock for healthcare providers without an individual prescription, subject to applicable conditions. Neither pathway makes a compounded product FDA-approved. Registration is not approval of the facility’s products. The linked Pharmacist guide explains the differences in more depth.
Read a claim without losing its limits
Begin with one answerable question. “Does it improve wellbeing?” covers many different things. Pain, sleep, muscle strength, a blood measurement and hospital admission are separate outcomes. Write the exact substance, the people studied, the comparison and the outcome before deciding whether a finding answers your question.
An online experience is a report of what someone noticed. It can identify questions worth investigating, including possible harms. It usually cannot separate the substance from changes in training, food, other treatments, expectations or the natural course of a problem. Many similar posts still do not create a controlled comparison. Popularity and scientific certainty are different measurements.
Laboratory and animal experiments can investigate mechanisms and generate hypotheses. Human observational studies examine associations in real settings, with potential differences between groups. Randomized comparisons are designed to reduce those differences, but their usefulness still depends on execution, size, follow-up and the outcomes measured. The study design must fit the question; a small trial is not automatically a complete safety record.
Keep benefit and harm in the same notes. Record how many people were observed, how long they were followed, what events occurred and whether investigators considered them related to treatment. An event after treatment does not by itself establish causation. Conversely, an uncertain causal connection is not a reason to erase a serious event.
When reading numbers, retain the denominator. A hypothetical change from 2 in 100 to 1 in 100 is a one-percentage-point absolute reduction and a 50% relative reduction. Both descriptions concern the same comparison. Ask for uncertainty around estimates and whether the result was planned or selected from many analyses. A headline alone rarely supplies all of this.
Read the source
Prepare a useful care conversation
You do not need technical training to ask a precise question. Start with what you want to understand: the diagnosis being considered, the evidence for an advertised outcome, the identity of a product, or the plan for follow-up. Bring the original link or document so the clinician can see the exact claim.
Prepare a short record of current medicines and supplements, allergies, relevant history and previous reactions. Include products discussed online without assuming that a familiar name accurately describes their contents. The purpose is to make the conversation more complete, not to diagnose yourself from a checklist.
Ask what outcomes matter in your circumstances and how benefit and harm would be assessed. “My laboratory number changed” and “my health improved” are different statements. A test can be useful, but its meaning depends on the clinical question and context. Ask why a test is relevant and what its result could change.
Clarify the people involved. The platform, prescriber, dispensing pharmacy, manufacturer and testing laboratory may be different organizations. Ask who can answer clinical questions, who can clarify product identity, and how records or concerns reach the right person. A sales representative is not automatically the person responsible for your care.
Leave with a written understanding of what remains uncertain, the next discussion and the route for follow-up. Ask how unexpected symptoms are handled and what the service cannot manage remotely.
What a test report can and cannot tell you
A certificate of analysis, often shortened to COA, describes tests on a particular sample. Start with its sample or lot number, date and issuing laboratory. Ask how that sample connects to the preparation being discussed with you. A report for raw ingredient, a different batch or an unidentified sample leaves that connection unanswered.
Next, read the test names rather than the largest percentage. Identity asks what was detected; a purity result describes a specified measurement of impurities relative to the main material. Neither result, by itself, tells you the amount in each finished container. Microbial testing, stability and clinical benefit are different questions. A blank or absent result means the report has not answered that question.
For example, a fictional report says “identity consistent” and “99% chromatographic purity.” You can accurately say those results were reported for that sample. You cannot turn them into “this preparation is sterile, contains the claimed amount and will improve my health.” Ask the clinician or pharmacist to explain the report’s scope and connection to the actual preparation. A clear explanation separates what was measured, what remains unknown and which document could answer the remaining question.
Where to report a problem and how to check a pharmacy
FDA MedWatch accepts reports of adverse events and product-quality problems. Record the product name, manufacturer or compounder, lot if available, dates, what happened and relevant packaging or photographs; distinguish what you observed from what you suspect caused it. A report communicates a concern and does not itself prove causation.
Use FDA BeSafeRx to learn how to evaluate an online pharmacy, then follow FDA’s state-pharmacy directory to the relevant board’s license lookup. Match the legal name and address, check the current license record and contact the board when an entry is unclear. A license lookup and a product-approval record answer different questions.
Reading path and books
Check the product category →
Approval belongs to a specific product and indication, not every item with a similar ingredient name.
Prepare a care conversation →
Bring questions about identity, oversight and follow-up to a qualified clinician.
Continue in the Church Library
Choose the depth that fits your background. Library entries include reading options and affiliate disclosures where applicable.
Testing Treatments — Evans, Thornton, Chalmers and Glasziou
Start with fair comparisons and uncertainty. The library entry includes an official free reading option. Published in 2011; use current official sources for regulatory questions.
The Body — Bill Bryson
An accessible introduction to human biology for readers who want context before technical papers. General science background, not a peptide treatment manual.
Examples in practice
These examples identify published resources and their uses; they are not evaluated services.
FDA — Is It Really FDA Approved?
Understand what approval, registration and listing do—and do not—establish.
FDA — BeSafeRx
Learn how to check an online pharmacy and find its state licensing record.
HHS — Preparing for a telehealth visit
Prepare your records, questions and connection before a remote appointment.
Questions and explanations
Was the result measured in people like me, or is that still unknown?
The answer depends on who entered the study and which outcome was measured. Compare participants’ health condition, age range and other eligibility criteria with the question you want answered; a similar age alone does not make the evidence applicable. For example, a study measuring glucose in adults with diabetes does not directly establish improved athletic recovery in otherwise healthy gym members. If that second outcome or population was not studied, write “not established by this study” rather than assuming the benefit carries over.
Which exact product, formulation and indication does the approval cover?
Look for the exact named medicine, dosage form, route and indication in its official approval record and current label. An ingredient name or facility registration does not establish that a different preparation has that approval. For example, an approved finished injectable medicine and a vial of bulk material bearing the same ingredient name are different product descriptions. Record what the label covers and leave any proposed use outside that description as a separate question for the clinician.
Read the source: it really fda approved
Who can explain whether the information applies to my health circumstances?
A licensed clinician who knows your history can discuss whether the evidence addresses your circumstances; a pharmacist can clarify medicine identity and formulation questions. Bring the actual claim plus your medicines, allergies and relevant health history so the conversation starts from specific information. For example, if an advertisement promises better sleep, ask whether the cited study measured sleep and whether your existing medicines or sleep problem change the discussion. A sales reply or a fictional website character cannot replace that individual assessment.
Glossary
- Comparator
- The reference group or intervention against which an outcome is compared, such as placebo or another treatment.
- Endpoint
- An outcome defined for a study. A biological measurement and a patient-important outcome are not necessarily the same thing.
- Formulation
- The composition and presentation of a product, including ingredients beyond the active substance.
- Adverse event
- An unwanted medical occurrence during observation; occurrence does not itself establish a causal connection to treatment.
- Investigational
- Under investigation. This describes research status, not proof of safety or benefit.
- COA
- Certificate of analysis: a report of specified tests and results for an identified material or sample. Its meaning depends on scope and provenance.
- Identity
- Whether a material matches the named substance within the methods and comparisons used.
- Purity
- A method-dependent assessment of detected components; chromatographic peak-area purity is not automatically total mass purity.
- Assay / content
- A measurement of the amount of a specified substance, stated with units and a defined basis.
- Potency
- Biological activity assessed by a specified assay; the term is sometimes used differently, so inspect the report’s definition.
- Sterility
- The absence of viable microorganisms; interpreting a sterility-test result requires its sampling and method context.
- Endotoxin
- A component of certain bacteria that can provoke inflammatory reactions. Endotoxin testing is distinct from sterility testing.
- Traceability
- A documented connection to an origin or reference. Measurement traceability and supply-chain provenance are related but different questions.
- Lot / batch
- An identified production group. Matching this identifier helps connect a document to the material it describes.
- Stability
- How a product’s measured properties change over time under specified storage conditions.
Make it useful
Appointment preparation
Use these prompts alongside your printable handbook.
Filled-in fictional example: Fictional example: Claim: “better recovery.” Source: an animal experiment. Unanswered: benefit in people with my condition. Appointment question: does any human study address this outcome?
- Write the claim you saw, its link and the date.
- List your medicines, allergies and the health question you want answered.
- Record what is known, what is uncertain and your most important concern.
- Ask who handles follow-up, unexpected symptoms and questions after the visit.
Read the source, not just the summary
U.S. educational orientation. Edition October 31, 2026. Review dates apply only to the identified sections; retained sources have not all been re-checked.
- FDA — Is It Really FDA Approved?
Registration and listing are not product approval. FDA does not approve healthcare providers.
- FDA — Compounding and FDA: Questions and Answers
Compounded drugs are not FDA-approved; oversight and conditions differ between 503A and 503B. Compounding can address particular patient needs.
- HHS — Preparing for a Telehealth Visit
Prepare medicines, allergies, questions and records; check cost, accessibility, privacy and technology.